Schmelzle Ex Rel. Schmelzle v. Alza Corp.

561 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 48254
CourtDistrict Court, D. Minnesota
DecidedJune 21, 2008
DocketCivil 06-4846
StatusPublished
Cited by6 cases

This text of 561 F. Supp. 2d 1046 (Schmelzle Ex Rel. Schmelzle v. Alza Corp.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Schmelzle Ex Rel. Schmelzle v. Alza Corp., 561 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 48254 (mnd 2008).

Opinion

MEMORANDUM OPINION AND ORDER

MICHAEL J. DAVIS, District Judge.

Plaintiff filed this wrongful death action in the District of Minnesota on December 11, 2006. Plaintiff has alleged that decedent died in Gillette, Wyoming on December 12, 2003, as a result of her use of Duragesic®, a fentanyl-containing, trans-dermal patch available only by prescription for the treatment of chronic pain. Plaintiff further alleges that the death of the decedent was caused by the wrongful acts or omissions of the manufacturer and its subsidiaries of the prescription drug Duragesic®.

It is Defendants’ position that this case has no connection to Minnesota. Plaintiff *1048 and the decedent resided in Wyoming during the relevant time period, and the decedent received all of her medical treatment in Wyoming. There are only three paragraphs in the Complaint that relate to Minnesota: ALZA is a Delaware corporation that has a facility in Minnesota where it designs and manufactures transdermal drug delivery patch systems (¶ 3), and that Janssen, a limited partnership organized and existing under the laws of the State of New Jersey, marketed and distributed Du-ragesic® in Minnesota (¶¶ 4 and 5).

At issue in this motion is which limitations period applies to Plaintiffs causes of action. Wyoming’s wrongful death statute has a two year limitations period that begins to run upon the death of the decedent. Wyo. Stat. § l-38-102(d). Minnesota’s wrongful death statute has a three year limitations period. Minn.Stat. § 573.02(1). Defendants argue that this issue must be determined by applying Minnesota’s choice of law principles.

A. Choice of Law Standard

In diversity cases, the forum state’s choice of law rules apply. Ferrell v. West Bend Mut. Ins. Co., 393 F.3d 786, 796 (8th Cir.2005). To decide whether a choice of law analysis is necessary, the Court first determines whether the rule of law at issue is procedural or substantive. Northwest Airlines, Inc. v. Astraea Aviation Servs., Inc., 111 F.3d 1386 at 1393 (8th Cir.1997). The parties agree that the rule of law at issue is substantive, therefore the Court should proceed to Minnesota’s choice of law analysis.

The first issue to be addressed is whether there is an actual conflict between the legal rules of the two states. Nodak Mut. Ins. Co. v. American Family Mut. Ins. Co., 590 N.W.2d 670, 672 (Minn.Ct.App.1999). “An actual conflict exists if choosing the rule of one state or the other is ‘outcome determinative.’ ” Id. Clearly, there is a conflict between the applicable Wyoming and Minnesota statute of limitations. If Wyoming law applies, this action is time-barred, if Minnesota law applies, it is not time-barred.

Because there is an actual conflict, this Court must apply a five factor test to determine which law should govern. Milkovich v. Saari, 295 Minn. 155, 203 N.W.2d 408 (1973). The factors are: 1) predictability of results; 2) maintenance of interstate order; 3) simplification of the judicial task; 4) advancement of the forum state’s interests; and 5) application of the better rule of law. Id., 295 Minn, at 161, 203 N.W.2d at 412. The factors are not to be mechanically applied, but are meant “to prompt the courts to carefully and critically consider each new fact situation and explain in a straightforward manner their choice of law.” Jepson v. General Casualty Company of Wisconsin, 513 N.W.2d 467, 470 (Minn.1994).

1. Predictability of Results

“Predictability of results as it relates to the tort aspect of a case is not of great importance in situations such as the one presented here because of the unplanned nature of automobile accidents.” Jepson, 513 N.W.2d at 470. Although this case does not involve a car accident, arguably a wrongful death action due to a prescription drug is similarly unplanned. Thus, this factor is not of importance.

2. Maintenance of Interstate Order

This factor concerns the assurance of “the free and unpenalized interstate movement of people and goods necessary to the success of the federal system.” Nodak, 590 N.W.2d at 673. “This requires deference to a sister state’s legal rules when that sister state has a substantial concern with the problem, even when the *1049 forum state also has an identifiable interest.” Id.

Defendants assert that of particular importance to this factor is the prevention of forum shopping. Jepson, 513 N.W.2d at 471. Plaintiff is a resident of Wyoming and the decedent resided there at all times relevant to the claims asserted. A Wyoming pharmacy dispensed the Duragesic® patch to the decedent and all heirs and next of kin reside in Wyoming. Plaintiff has not alleged in the Complaint that Du-ragesic® was designed or manufactured in Minnesota. Under these circumstances, Wyoming has a more substantial connection to this case. Defendants argue that by not filing this action in Wyoming, Plaintiff was trying to avoid the applicable Wyoming limitations period. Thus, application of Wyoming law would prevent forum shopping.

Plaintiff responds that the Defendants have minimal contacts with the state of Wyoming. By contrast, Defendants have had annual sales of Duragesic® of $50,000,000 in Minnesota between 2002 and 2006. No comparable sales figures were provided for Wyoming. Plaintiff further notes that ALZA does research and develops transdermal patches in Fridley, Minnesota. Plaintiff argues that as scientific knowledge concerning transdermal fentanyl systems does not exist in a vacuum, the knowledge of safety risks associated with fentanyl is common to researchers at the Fridley facility as well as to those responsible for the design, marketing and sale of the patch at issue, Duragesic®. Given Defendants’ connection to Minnesota, Plaintiff argues that forum shopping is not implicated in this case. Finally, Plaintiff notes that as of August 15, 2007, there have been 721 reports of adverse events associated with Duragesic® in Minnesota, compared to 56 in Wyoming.

This Court has previously held that maintenance of interstate order weighs in favor of the state that has the most significant contacts with the facts relevant to the litigation. In re Baycol Prods. Litig., 218 F.R.D. 197, 207 (D.Minn.2003) (this factor weighs in favor of applying the law of the state in which the plaintiff resides, and where the drug was prescribed.). As applied to this case, Plaintiff is a lifelong resident of Wyoming, and facts surrounding the circumstances of the decedent using Duragesic® took place in Wyoming. Furthermore, there is no allegation that Duragesic® was designed or manufactured in Minnesota.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hernandez v. Ecolab, Inc.
D. Minnesota, 2023
Fairfax Financial Holdings Limited v. S.A.C.
160 A.3d 44 (New Jersey Superior Court App Division, 2017)
Andrew McCarrell v. Hoffman-La Roach, Inc.(076524)
153 A.3d 207 (Supreme Court of New Jersey, 2017)

Cite This Page — Counsel Stack

Bluebook (online)
561 F. Supp. 2d 1046, 2008 U.S. Dist. LEXIS 48254, Counsel Stack Legal Research, https://law.counselstack.com/opinion/schmelzle-ex-rel-schmelzle-v-alza-corp-mnd-2008.